Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Share-based Compensation (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Share-based Compensation readings, the most recent being $749000.0 for Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 82.2% to $749000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $6.3 million, a 72.42% decrease, with the full-year FY2025 number at $9.8 million, down 63.88% from a year prior.
  • Share-based Compensation hit $749000.0 in Q1 2026 for Atara Biotherapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.3 million in Q1 2022 to a low of $749000.0 in Q1 2026.
  • Median Share-based Compensation over the past 5 years was $8.4 million (2024), compared with a mean of $8.0 million.
  • Biggest five-year swings in Share-based Compensation: fell 11.09% in 2023 and later crashed 82.2% in 2026.
  • Atara Biotherapeutics' Share-based Compensation stood at $11.4 million in 2022, then fell by 12.64% to $9.9 million in 2023, then tumbled by 41.11% to $5.8 million in 2024, then tumbled by 74.05% to $1.5 million in 2025, then crashed by 50.63% to $749000.0 in 2026.
  • The last three reported values for Share-based Compensation were $749000.0 (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025) per Business Quant data.